1
Clinical Trials associated with Ad5F35-LMP1/LMP2-transduced autologous dendritic cells(National Cancer Centre of Singapore Pte) / Unknown statusPhase 2IIT Phase II Clinical Trial of Tumour Vaccination By Intradermal Delivery of Autologous Dendritic Cells Transduced With Adenoviral Vector (AD5F35) Expressing Latent Membrane Protein-1 (LMP-1) and Latent Membrane Protein-2 (LMP-2) Genes in Combination With Celecoxib in Patient With Metastatic Nasopharyngeal Carcinoma
RATIONALE: Vaccines made from a gene-modified virus and a person's dendritic cells may help the body build an effective immune response to kill tumor cells. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vaccine therapy together with celecoxib may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving vaccine therapy together with celecoxib works in treating patients with metastatic nasopharyngeal cancer.
100 Clinical Results associated with Ad5F35-LMP1/LMP2-transduced autologous dendritic cells(National Cancer Centre of Singapore Pte)
100 Translational Medicine associated with Ad5F35-LMP1/LMP2-transduced autologous dendritic cells(National Cancer Centre of Singapore Pte)
100 Patents (Medical) associated with Ad5F35-LMP1/LMP2-transduced autologous dendritic cells(National Cancer Centre of Singapore Pte)
100 Deals associated with Ad5F35-LMP1/LMP2-transduced autologous dendritic cells(National Cancer Centre of Singapore Pte)